JP2023507981A5 - - Google Patents

Info

Publication number
JP2023507981A5
JP2023507981A5 JP2022537240A JP2022537240A JP2023507981A5 JP 2023507981 A5 JP2023507981 A5 JP 2023507981A5 JP 2022537240 A JP2022537240 A JP 2022537240A JP 2022537240 A JP2022537240 A JP 2022537240A JP 2023507981 A5 JP2023507981 A5 JP 2023507981A5
Authority
JP
Japan
Prior art keywords
seq
approximately
composition
less
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064241 external-priority patent/WO2021126657A1/en
Publication of JP2023507981A publication Critical patent/JP2023507981A/ja
Publication of JP2023507981A5 publication Critical patent/JP2023507981A5/ja
Priority to JP2025185522A priority Critical patent/JP2026027328A/ja
Pending legal-status Critical Current

Links

JP2022537240A 2019-12-18 2020-12-10 生物医薬組成物および関連の方法 Pending JP2023507981A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025185522A JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US62/949,696 2019-12-18
US201962950595P 2019-12-19 2019-12-19
US62/950,595 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025185522A Division JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Publications (2)

Publication Number Publication Date
JP2023507981A JP2023507981A (ja) 2023-02-28
JP2023507981A5 true JP2023507981A5 (cg-RX-API-DMAC10.html) 2023-12-19

Family

ID=74125707

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537240A Pending JP2023507981A (ja) 2019-12-18 2020-12-10 生物医薬組成物および関連の方法
JP2025185522A Pending JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025185522A Pending JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Country Status (11)

Country Link
US (1) US20230059341A1 (cg-RX-API-DMAC10.html)
EP (1) EP4077388A1 (cg-RX-API-DMAC10.html)
JP (2) JP2023507981A (cg-RX-API-DMAC10.html)
KR (1) KR20220129548A (cg-RX-API-DMAC10.html)
CN (1) CN115298218A (cg-RX-API-DMAC10.html)
AU (2) AU2020407007A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022014694A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164600A1 (cg-RX-API-DMAC10.html)
IL (1) IL293753A (cg-RX-API-DMAC10.html)
MX (1) MX2022007464A (cg-RX-API-DMAC10.html)
WO (1) WO2021126657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355757A1 (en) * 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
EP4626927A1 (en) * 2022-11-30 2025-10-08 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies
EP4763222A1 (en) * 2025-08-25 2026-06-24 Qilu Pharmaceutical Co., Ltd. A composition comprising apitegromab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3357508A4 (en) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Similar Documents

Publication Publication Date Title
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2022000436A (ja) 高濃度抗体製剤
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2020518599A5 (cg-RX-API-DMAC10.html)
AU2018263837A1 (en) Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
JP2022532927A5 (cg-RX-API-DMAC10.html)
US20230116380A1 (en) Long-acting gm-csf and methods of use
US20220008533A1 (en) Composition and methods of treating inflammatory and autoimmune diseases
JP2022126791A (ja) Il-17アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US20250011416A1 (en) Methods for the treatment of cardiovascular disease
JP2026506286A (ja) ミオスタチン活性化の選択的且つ強力な阻害抗体
JP2023182834A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2019513748A5 (cg-RX-API-DMAC10.html)
TW201536320A (zh) 治療骨性關節炎之組合物及方法
JP2024540395A5 (cg-RX-API-DMAC10.html)
CN111886252A (zh) 促进胰岛细胞生长的方法
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
Graul et al. The year's new drugs and biologics 2019
WO2025072725A9 (en) Methods for the treatment of cardiovascular disease
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
WO2025094976A1 (ja) ヘモジデリンの沈着及び/又は滑膜肥厚の改善又は抑制剤
JP2023539736A5 (cg-RX-API-DMAC10.html)
CN119630422A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease